Adicet bio to participate in 2023 canaccord genuity horizons in oncology virtual conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced that chen schor, president and chief executive officer will participate in a panel at the canaccord genuity horizons in oncology virtual conference being held april 20, 2023. details of the event are as follows: panel: “off-the-shelf cart – current snapshot” date: thursday, april 20, 2023 time: 11:00 a.m. et the adicet bio team will be available for one-on-one meetings throughout the conference. please contact your sales representative at canaccord genuity to register for a meeting with the company. about adicet bio, inc. adicet bio, inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer. adicet is advancing a pipeline of “off-the-shelf” gamma delta t cells, engineered with chimeric antigen receptors (cars) and chimeric antigen adaptors (cads), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. for more information, please visit our website at https://www.adicetbio.com.
ACET Ratings Summary
ACET Quant Ranking